Kovach Jaclyn L, Rosenfeld Philip J
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Retina. 2009 Jan;29(1):27-32. doi: 10.1097/IAE.0b013e31818ba9de.
To determine if inhibition of vascular endothelial growth factor-A affects visual acuity, fluorescein angiographic, and optical coherence tomography outcomes in patients with perifoveal telangiectasia (PT), also referred to as macular telangiectasia, Type 2 and previously known as juxtafoveolar retinal telangiectasis group 2A.
A retrospective review of patients with PT treated with intravitreal bevacizumab was performed at the Bascom Palmer Eye Institute. Best-corrected visual acuity, fluorescein angiography, and optical coherence tomography measurements were performed.
Nine eyes of eight patients were identified. Five of these eyes had proliferative PT characterized by subretinal neovascularization involving the macula. After treatment, follow-up ranged from 4 to 27 months. The mean best-corrected visual acuity remained stable for the four eyes with nonproliferative PT. In the five eyes with proliferative PT, best-corrected visual acuity was unchanged or improved after treatment. All eyes demonstrated decreased intraretinal leakage on fluorescein angiography after an injection of bevacizumab, and eyes with proliferative PT showed decreased growth and leakage of the subretinal neovascularization. The mean decrease in optical coherence tomography central retinal thickness was less than 30 mum.
In nonproliferative PT, intravitreal bevacizumab decreases fluorescein angiographic leakage in PT but has no short-term effect on visual acuity or optical coherence tomography appearance. In proliferative PT, intravitreal bevacizumab arrests the leakage and growth of subretinal neovascularization with the possibility of visual acuity improvement.
确定抑制血管内皮生长因子-A是否会影响中心凹周围毛细血管扩张症（PT，也称为黄斑毛细血管扩张症2型，以前称为近中心凹视网膜毛细血管扩张症2A组）患者的视力、荧光素血管造影和光学相干断层扫描结果。
在巴斯科姆·帕尔默眼科研究所对接受玻璃体内注射贝伐单抗治疗的PT患者进行回顾性研究。进行最佳矫正视力、荧光素血管造影和光学相干断层扫描测量。
确定了8例患者的9只眼。其中5只眼患有增殖性PT，其特征为黄斑区视网膜下新生血管形成。治疗后，随访时间为4至27个月。4只非增殖性PT眼的平均最佳矫正视力保持稳定。在5只增殖性PT眼中，治疗后最佳矫正视力未改变或有所改善。所有眼在注射贝伐单抗后荧光素血管造影显示视网膜内渗漏减少，增殖性PT眼的视网膜下新生血管生长和渗漏减少。光学相干断层扫描测量的中心视网膜厚度平均减少小于30μm。
在非增殖性PT中，玻璃体内注射贝伐单抗可减少PT的荧光素血管造影渗漏，但对视力或光学相干断层扫描表现无短期影响。在增殖性PT中，玻璃体内注射贝伐单抗可阻止视网膜下新生血管的渗漏和生长，有可能改善视力。
